Developments in glucocorticoid therapy.

Academic Article


  • Recent evidence for a disease-modifying potential of low-dose glucocorticoids (GCs) in the treatment of rheumatoid arthritis has renewed the debate on the risk benefit ratio with this therapy. Two recent developments are described that might have a positive influence on these risk benefit ratios. One is the improvement in new GC compounds--designer GCs, alterations in bioactivity, and alterations in formulations. The other is a better understanding and management of the toxicity of GCs.
  • Authors


  • Animals, Chemistry, Pharmaceutical, Designer Drugs, Glucocorticoids, Humans, Receptors, Glucocorticoid, Rheumatic Diseases
  • Digital Object Identifier (doi)

    Author List

  • Bijlsma JWJ; Saag KG; Buttgereit F; da Silva JAP
  • Start Page

  • 1
  • End Page

  • vii
  • Volume

  • 31
  • Issue

  • 1